<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.immunityageing.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Immunity &amp; Ageing - Latest Articles</title>
        <link>http://www.immunityageing.com</link>
        <description>The latest research articles published by Immunity &amp; Ageing</description>
        <dc:date>2011-12-02T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/12" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/11" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/10" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/9" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/8" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/7" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/6" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/5" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/8/1/3" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.immunityageing.com/content/8/1/12">
        <title>Immunopathogenesis of Primary biliary cirrhosis:  An old wives&apos; tale</title>
        <description>Primary biliary cirrhosis (PBC) is a cholestatic liver disease characterised by the autoimmune destruction of the small intrahepatic bile ducts. The disease has an unpredictable clinical course, but may progress to fibrosis and cirrhosis. Although medical treatment with urseodeoxycholic acid is largely successful, some patients may progress to liver failure requiring liver transplantation. PBC is characterised by the presence of disease specific anti-mitochondrial (AMA) antibodies, which are pathognomonic for PBC development. The disease demonstrates an overwhelming female preponderance and virtually all women with PBC present in middle age. The reasons for this are unknown; however several environmental and immunological factors may be involved. As the immune systems ages, it become less self tolerant, and mounts a weaker response to pathogens, possibly leading to cross reactivity or molecular mimicry. Some individuals display immunological changes which encourage the development of autoimmune disease. Risk factors implicated in PBC include recurrent urinary tract infection in females, as well as an increased prevalence of reproductive complications. These risk factors may work in concert with and possibly even accelerate, immune system ageing, contributing to PBC development. This review will examine the changes that occur in the immune system with ageing, paying particular attention to those changes which contribute to the development of autoimmune disease with increasing age. The review also discusses risk factors which may account for the increased female predominance of PBC, such as recurrent UTI and oestrogens.</description>
        <link>http://www.immunityageing.com/content/8/1/12</link>
                <dc:creator>Daniel Smyk</dc:creator>
                <dc:creator>Eirini Rigopoulou</dc:creator>
                <dc:creator>Ana Lleo</dc:creator>
                <dc:creator>Robin Abeles</dc:creator>
                <dc:creator>Athanasios Mavropoulos</dc:creator>
                <dc:creator>Charalambos Billinis</dc:creator>
                <dc:creator>Pietro Invernizzi</dc:creator>
                <dc:creator>Dimitrios Bogdanos</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:12</dc:source>
        <dc:date>2011-12-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-12</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-12-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2011-12-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/11">
        <title>Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naive T lymphocytes</title>
        <description>MicroRNA (miR)-17-92a expression plays a crucial role in lymphocyte ontogeny. We therefore set out to determine miR-92a expression levels in peripheral blood lymphocytes from healthy subjects to ascertain any association between these levels and ageing. We found a positive correlation between the miR-92a expression level and the percentages of RO-CD8+CD27+ (P = 0.0046) and CD3+CD8+CD62L+ (P = 0.0011). This suggests that the majority of miR-92a of CD8+ T cells is derived from na&#239;ve cells, and the miR-92a expression level in CD8+ T cells declines progressively with age. These results indicate that the age-related attrition of na&#239;ve T cells is linked to a reduction of miR-92a in human T -lymphocytes. Therefore, we should careful attention when evaluating human miRNA levels in T lymphocytes to use normal control values.</description>
        <link>http://www.immunityageing.com/content/8/1/11</link>
                <dc:creator>Michiyo Ohyashiki</dc:creator>
                <dc:creator>Junko Ohyashiki</dc:creator>
                <dc:creator>Ayako Hirota</dc:creator>
                <dc:creator>Chiaki Kobayashi</dc:creator>
                <dc:creator>Kazuma Ohyashiki</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:11</dc:source>
        <dc:date>2011-11-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-11</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-11-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2011-11-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/10">
        <title>Report from the Second Cytomegalovirus and Immunosenescence Workshop</title>
        <description>The Second International Workshop on CMV &amp; Immunosenescence was held in Cambridge, UK, 2-4th December, 2010. The presentations covered four separate sessions: cytomegalovirus and T cell phenotypes; T cell memory frequency, inflation and immunosenescence; cytomegalovirus in aging, mortality and disease states; and the immunobiology of cytomegalovirus-specific T cells and effects of the virus on vaccination. This commentary summarizes the major findings of these presentations and references subsequently published work from the presenter laboratory where appropriate and draws together major themes that were subsequently discussed along with new areas of interest that were highlighted by this discussion.</description>
        <link>http://www.immunityageing.com/content/8/1/10</link>
                <dc:creator>Mark Wills</dc:creator>
                <dc:creator>Arne Akbar</dc:creator>
                <dc:creator>Mark Beswick</dc:creator>
                <dc:creator>Jos Bosch</dc:creator>
                <dc:creator>Calogero Caruso</dc:creator>
                <dc:creator>Giuseppina Colonna-Romano</dc:creator>
                <dc:creator>Ambarish Dutta</dc:creator>
                <dc:creator>Claudio Franceschi</dc:creator>
                <dc:creator>Tamas Fulop</dc:creator>
                <dc:creator>Effrossyni Gkrania-Klotsas</dc:creator>
                <dc:creator>Joerg Goronzy</dc:creator>
                <dc:creator>Stephen Griffiths</dc:creator>
                <dc:creator>Sian Henson</dc:creator>
                <dc:creator>Dietmar Herndler-Brandstetter</dc:creator>
                <dc:creator>Ann Hill</dc:creator>
                <dc:creator>Florian Kern</dc:creator>
                <dc:creator>Paul Klenerman</dc:creator>
                <dc:creator>Derek Macallan</dc:creator>
                <dc:creator>Richard Macualay</dc:creator>
                <dc:creator>Andrea Maier</dc:creator>
                <dc:creator>Gavin Mason</dc:creator>
                <dc:creator>David Melzer</dc:creator>
                <dc:creator>Matthew Morgan</dc:creator>
                <dc:creator>Paul Moss</dc:creator>
                <dc:creator>Janko Nikolich-Zugich</dc:creator>
                <dc:creator>Annette Pachnio</dc:creator>
                <dc:creator>Natalie Riddell</dc:creator>
                <dc:creator>Ryan Roberts</dc:creator>
                <dc:creator>Paolo Sansoni</dc:creator>
                <dc:creator>Delphine Sauce</dc:creator>
                <dc:creator>John Sinclair</dc:creator>
                <dc:creator>Rafael Solana</dc:creator>
                <dc:creator>Jan Strindhall</dc:creator>
                <dc:creator>Piotr Trzonkowski</dc:creator>
                <dc:creator>Rene van Lier</dc:creator>
                <dc:creator>Rosanna Vescovini</dc:creator>
                <dc:creator>George Wang</dc:creator>
                <dc:creator>Rudi Westendorp</dc:creator>
                <dc:creator>Graham Pawelec</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:10</dc:source>
        <dc:date>2011-10-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-10</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-10-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2011-10-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/9">
        <title>Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells</title>
        <description>Background:
Old age is associated with increased levels of circulating pro-inflammatory cytokines, a phenomenon termed inflamm-aging. Elevated levels of pro-inflammatory cytokines have been associated with several age-associated diseases and with a shortened lifespan. Indoleamine 2,3-dioxygenase (IDO) has immunomodulatory properties and its activity is elevated in inflammation, autoimmune disorders and malignancies. We have previously shown that IDO activity is increased in nonagenarians compared to young individuals and that high IDO activity is associated with mortality at old age.FindingsIn this study our aim was to assess whether this difference in IDO activity in the plasma was due to the differential expression of either the IDO1 or IDO2 gene in peripheral blood mononuclear cells. Our results show that IDO1 and IDO2 are not differently expressed in nonagenarians compared to controls and that the expression of IDO genes is not associated with the level of IDO activity in the plasma.
Conclusion:
The level of IDO activity in the plasma is not regulated through the expression of IDO1 or IDO2 in the peripheral blood mononuclear cells.</description>
        <link>http://www.immunityageing.com/content/8/1/9</link>
                <dc:creator>Saara Marttila</dc:creator>
                <dc:creator>Juulia Jylhava</dc:creator>
                <dc:creator>Carita Eklund</dc:creator>
                <dc:creator>Antti Hervonen</dc:creator>
                <dc:creator>Marja Jylha</dc:creator>
                <dc:creator>Mikko Hurme</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:9</dc:source>
        <dc:date>2011-10-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-9</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-9-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2011-10-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/8">
        <title>Immune risk phenotype is associated with nosocomial lung infections in elderly in-patients</title>
        <description>Background:
Nosocomial infections are extremely common in the elderly and may be related to ageing of the immune system. The Immune Risk Phenotype (IRP), which predicts shorter survival in elderly patients, has not been evaluated as a possible risk factor for nosocomial infection. Our aim was to assess the prevalence of nosocomial infections in elderly in-patients and to investigate potential relationships between nosocomial infections and the immunophenotype, including IRP parameters.
Results:
We included 252 consecutive in-patients aged 70 years or over (mean age, 85 &#177; 6.2 years), between 2006 and 2008. Among them, 97 experienced nosocomial infections, yielding a prevalence rate of 38.5% (95% confidence interval, 32.5-44.5). The main infection sites were the respiratory tract (21%) and urinary tract (17.1%) When we compared immunological parameters including cell counts determined by flow cytometry in the groups with and without nosocomial infections, we found that the group with nosocomial infections had significantly lower values for the CD4/CD8 ratio and naive CD8 and CD4 T-cell counts and higher counts of memory CD8 T-cells with a significant increase in CD28-negative CD8-T cells. Neither cytomegalovirus status (positive in 193/246 patients) nor presence of the IRP was associated with nosocomial infections. However, nosocomial pneumonia was significantly more common among IRP-positive patients than IRP-negative patients (17/60 versus 28/180; p = 0.036).
Conclusion:
Immunological parameters that are easy to determine in everyday practice and known to be associated with immune system ageing and shorter survival in the elderly are also associated with an elevated risk of nosocomial pneumonia in the relatively short term.</description>
        <link>http://www.immunityageing.com/content/8/1/8</link>
                <dc:creator>A Plonquet</dc:creator>
                <dc:creator>S Bastuji-Garin</dc:creator>
                <dc:creator>F Tahmasebi</dc:creator>
                <dc:creator>C Brisacier</dc:creator>
                <dc:creator>K Ledudal</dc:creator>
                <dc:creator>Jp Farcet</dc:creator>
                <dc:creator>E Paillaud</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:8</dc:source>
        <dc:date>2011-10-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-8</dc:identifier>
                            <dc:title>Immune factors linked to hospital infections in elderly</dc:title>
                            <dc:description>Elderly patients who contract in-hospital infections exhibit altered immune parameters (e.g high memory T Cells) compared to those without infection, which should be taken into consideration when developing care plans.</dc:description>
                <prism:require>/content/figures/1742-4933-8-8-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2011-10-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/7">
        <title>The &quot;Alzheimer&apos;s disease signature&quot;: potential perspectives for novel biomarkers. </title>
        <description>Alzheimer&apos;s disease is a progressive and neurodegenerative disorder which involves multiple molecular mechanisms. Intense research during the last years has accumulated a large body of data and the search for sensitive and specific biomarkers has undergone a rapid evolution. However, the diagnosis remains problematic and the current tests do not accurately detect the process leading to neurodegeneration. Biomarkers discovery and validation are considered the key aspects to support clinical diagnosis and provide discriminatory power between different stages of the disorder. A considerable challenge is to integrate different types of data from new potent approach to reach a common interpretation and replicate the findings across studies and populations. Furthermore, long-term clinical follow-up and combined analysis of several biomarkers are among the most promising perspectives to diagnose and manage the disease. The present review will focus on the recent published data providing an updated overview of the main achievements in the genetic and biochemical research of the Alzheimer&apos;s disease. We also discuss the latest and most significant results that will help to define a specific disease signature whose validity might be clinically relevant for future AD diagnosis.</description>
        <link>http://www.immunityageing.com/content/8/1/7</link>
                <dc:creator>Sergio Davinelli</dc:creator>
                <dc:creator>Mariano Intrieri</dc:creator>
                <dc:creator>Claudio Russo</dc:creator>
                <dc:creator>Alfonso Di Costanzo</dc:creator>
                <dc:creator>Davide Zella</dc:creator>
                <dc:creator>Paolo Bosco</dc:creator>
                <dc:creator>Giovanni Scapagnini</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:7</dc:source>
        <dc:date>2011-09-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-7</dc:identifier>
                            <dc:title>Novel biomarkers key to Alzheimers signature</dc:title>
                            <dc:description>Davinelli et al. review potential biomarker candidates from the latest research, which could hold the key to the Alzheimer&apos;s disease signature, providing a way of diagnosing the disease and its progressive stages.</dc:description>
                <prism:require>/content/figures/1742-4933-8-7-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2011-09-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/6">
        <title>Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors</title>
        <description>Background:
While influenza vaccination results in protective antibodies against primary infections, clearance of infection is primarily mediated through CD8+ T cells. Studying the CD8+ T cell response to influenza epitopes is crucial in understanding the disease associated morbidity and mortality especially in at risk populations such as the elderly. We compared the CD8+ T cell response to immunodominant and subdominant influenza epitopes in HLA-A2+ control, adult donors, aged 21-42, and in geriatric donors, aged 65 and older.
Results:
We used a novel artificial Antigen Presenting Cell (aAPC) based stimulation assay to reveal responses that could not be detected by enzyme-linked immunosorbent spot (ELISpot). 14 younger control donors and 12 geriatric donors were enrolled in this study. The mean number of influenza-specific subdominant epitopes per control donor detected by ELISpot was only 1.4 while the mean detected by aAPC assay was 3.3 (p = 0.0096). Using the aAPC assay, 92% of the control donors responded to at least one subdominant epitopes, while 71% of control donors responded to more than one subdominant influenza-specific response. 66% of geriatric donors lacked a subdominant influenza-specific response and 33% of geriatric donors responded to only 1 subdominant epitope. The difference in subdominant response between age groups is statistically significant (p = 0.0003).
Conclusion:
Geriatric donors lacked the broad, multi-specific response to subdominant epitopes seen in the control donors. Thus, we conclude that aging leads to a decrease in the subdominant influenza-specific CTL responses which may contribute to the increased morbidity and mortality in older individuals.</description>
        <link>http://www.immunityageing.com/content/8/1/6</link>
                <dc:creator>Jessica Lee</dc:creator>
                <dc:creator>Mathias Oelke</dc:creator>
                <dc:creator>Lakshmi Ramachandra</dc:creator>
                <dc:creator>David Canaday</dc:creator>
                <dc:creator>Jonathan Schneck</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:6</dc:source>
        <dc:date>2011-08-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-6</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-6-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2011-08-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/5">
        <title>Identification of serum biomarkers for aging and anabolic response</title>
        <description>ObjectiveWith the progressive aging of the human population, there is an inexorable decline in muscle mass, strength and function. Anabolic supplementation with testosterone has been shown to effectively restore muscle mass in both young and elderly men. In this study, we were interested in identifying serum factors that change with age in two distinct age groups of healthy men, and whether these factors were affected by testosterone supplementation.
Methods:
We measured the protein levels of a number of serum biomarkers using a combination of banked serum samples from older men (60 to 75 years) and younger men (ages 18 to 35), as well as new serum specimens obtained through collaboration. We compared baseline levels of all biomarkers between young and older men. In addition, we evaluated potential changes in these biomarker levels in association with testosterone dose (low dose defined as 125 mg per week or below compared to high dose defined as 300 mg per week or above) in our banked specimens.
Results:
We identified nine serum biomarkers that differed between the young and older subjects. These age-associated biomarkers included: insulin-like growth factor (IGF1), N-terminal propeptide of type III collagen (PIIINP), monokine induced by gamma interferon (MIG), epithelial-derived neutrophil-activating peptide 78 (ENA78), interleukin 7 (IL-7), p40 subunit of interleukin 12 (IL-12p40), macrophage inflammatory protein 1&#946; (MIP-1&#946;), platelet derived growth factor &#946; (PDGF&#946;) and interferon-inducible protein 10 (IP-10). We further observed testosterone dose-associated changes in some but not all age related markers: IGF1, PIIINP, leptin, MIG and ENA78. Gains in lean mass were confirmed by dual energy X-ray absorptiometry (DEXA).
Conclusions:
Results from this study suggest that there are potential phenotypic biomarkers in serum that can be associated with healthy aging and that some but not all of these biomarkers reflect gains in muscle mass upon testosterone administration.</description>
        <link>http://www.immunityageing.com/content/8/1/5</link>
                <dc:creator>Camellia Banerjee</dc:creator>
                <dc:creator>Jagadish Ulloor</dc:creator>
                <dc:creator>Edgar Dillon</dc:creator>
                <dc:creator>Qusai Dahodwala</dc:creator>
                <dc:creator>Brittani Franklin</dc:creator>
                <dc:creator>Paola Sebastiani</dc:creator>
                <dc:creator>Melinda Sheffield-Moore</dc:creator>
                <dc:creator>Randall Urban</dc:creator>
                <dc:creator>Shalender Bhasin</dc:creator>
                <dc:creator>Monty Montano</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:5</dc:source>
        <dc:date>2011-06-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-5</dc:identifier>
                            <dc:title>Testosterone masks some ageing biomarkers</dc:title>
                            <dc:description>Testosterone supplements have been shown to affect levels of certain ageing biomarkers, providing a potential gauge to trace the response to these therapeutic supplements in elderly patients aiming to improve muscle mass.</dc:description>
                <prism:require>/content/figures/1742-4933-8-5-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2011-06-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/4">
        <title>Inflammatory and Immunological parameters in adults with Down syndrome

</title>
        <description>Background:
The increase in life expectancy within the general population has resulted in an increasing number of elderly adults, including patients with Down syndrome (DS), with a current life expectancy of about 50 years. We evaluate the parameters of humoral and cellular immune response, the quantitative expression of the regulator of calcineurin1 gene (RCAN1) and the production of cytokines. The study group consisted of adults DS (n = 24) and a control group with intellectual disability without Down syndrome (ID) (n = 21) and living in a similar environmental background. It was evaluated serology, immunophenotyping, the quantitative gene expression of RCAN1 and the production of cytokines.
Results:
In the DS group, the results showed an increase in NK cells, CD8, decreased CD19 (p &lt; 0.05) and an increase spontaneous production of IFNgamma, TNFalpha and IL-10 (p &lt; 0.05). There was not any difference in RCAN1 gene expression between the groups.
Conclusions:
These data suggest a similar humoral response in the two groups. The immunophenotyping suggests sign of premature aging of the immune system and the cytokine production show a proinflammatory profile.</description>
        <link>http://www.immunityageing.com/content/8/1/4</link>
                <dc:creator>Maria Trotta</dc:creator>
                <dc:creator>Joao Serro Azul</dc:creator>
                <dc:creator>Mauricio Wajngarten</dc:creator>
                <dc:creator>Simone Fonseca</dc:creator>
                <dc:creator>Anna Goldberg</dc:creator>
                <dc:creator>Jorge Kalil</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:4</dc:source>
        <dc:date>2011-04-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-4</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-4-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2011-04-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/8/1/3">
        <title>Cytomegalovirus antibodies in dried blood spots: a minimally invasive method for assessing stress, immune function, and aging</title>
        <description>Background:
Cytomegalovirus (CMV) is a prevalent herpesvirus with links to both stress and aging. This paper describes and validates a minimally invasive method for assessing antibodies against CMV in finger stick whole blood spot samples for use as an indirect marker of an aspect of cell-mediated immunity.
Results:
Analysis of CMV in dried blood spot samples (DBS) was based on modifications of a commercially available protocol for quantifying CMV antibodies in serum or plasma. The method was evaluated through analysis of precision, reliability, linearity, and correlation between matched serum and DBS samples collected from 75 volunteers. Correlation between DBS and plasma values was linear and high (Pearson correlation R = .96), and precision, reliability, and linearity of the DBS assay were within acceptable ranges.
Conclusions:
The validity of a DBS assay for CMV antibodies will enable its inclusion in population-based surveys and other studies collecting DBS samples in non-clinical settings, increasing scientific understanding of the interaction of social and biological stress and immune function.</description>
        <link>http://www.immunityageing.com/content/8/1/3</link>
                <dc:creator>Jennifer Dowd</dc:creator>
                <dc:creator>Allison Aiello</dc:creator>
                <dc:creator>Laura Chyu</dc:creator>
                <dc:creator>Yuan-yen Huang</dc:creator>
                <dc:creator>Thomas McDade</dc:creator>
                <dc:source>Immunity &amp; Ageing 2011, null:3</dc:source>
        <dc:date>2011-01-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-8-3</dc:identifier>
                                <prism:require>/content/figures/1742-4933-8-3-toc.gif</prism:require>
                <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2011-01-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

